UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2279-4
Program Prior Authorization/Medical Necessity
Medication Vijoice® (alpelisib)
P&T Approval Date 6/2022, 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Vijoice® (alpelisib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients
2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum
(PROS) who require systemic therapy. This indication is approved under accelerated approval
based on response rate and duration of response. Continued approval for this indication may be
contingent upon verification and description of clinical benefit in a confirmatory trial(s).
2. Coverage Criteriaa:
A. Initial Authorization
1. Vijoice will be approved based on ALL of the following criteria:
a. Diagnosis of PIK3CA-Related Overgrowth Spectrum (PROS)
-AND-
b. One of the following criteria:
(1) Confirmed presence of a mutation in the PIK3CA gene
-OR-
(2) One of the following:
(a) Two or more of the following spectrum features:
i. Overgrowth: adipose, muscle, nerve, skeletal
ii. Vascular malformations: capillary, venous, arteriovenous, lymphatic
iii. Epidermal nevus
-OR-
(b) One or more of the following isolated features:
i. Large isolated lymphatic malformation
ii. Isolated macrodactyly or overgrown splayed feet/ hands with overgrown
limbs
iii. Truncal adipose overgrowth
iv. Hemimegalencephaly (bilateral) / dysplastic megalencephaly / focal
cortical dysplasia
v. Epidermal nevus
© 2025 UnitedHealthcare Services Inc.
1
vi. Seborrheic keratoses
vii. Benign lichenoid keratoses
-AND-
c. Patient is 2 years of age or older
-AND-
d. Patient has severe manifestations of PROS requiring systemic therapy
-AND-
e. Prescribed by, or in consultation with, a clinical geneticist or a practitioner who has
specialized expertise in the management of PROS manifestations
Authorization will be issued for 12 months.
B. Reauthorization
1. Vijoice will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Vijoice therapy
-AND-
b. Prescribed by, or in consultation with, a clinical geneticist or a practitioner who has
specialized expertise in the management of PROS manifestations
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Vijoice [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2024.
2. Keppler-Noreuil, K. M., Rios, J. J., Parker, V. E., Semple, R. K., Lindhurst, M. J., Sapp, J. C.,
Alomari, A., Ezaki, M., Dobyns, W., & Biesecker, L. G. (2015). PIK3CA-related overgrowth
spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
© 2025 UnitedHealthcare Services Inc.
2
American journal of medical genetics. Part A, 167A(2), 287–295.
https://doi.org/10.1002/ajmg.a.36836
3. Venot, Q., Blanc, T., Rabia, S. H., Berteloot, L., Ladraa, S., Duong, J. P., Blanc, E., Johnson, S.
C., Hoguin, C., Boccara, O., Sarnacki, S., Boddaert, N., Pannier, S., Martinez, F., Magassa, S.,
Yamaguchi, J., Knebelmann, B., Merville, P., Grenier, N., Joly, D., … Canaud, G. (2018).
Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature, 558(7711),
540–546. https://doi.org/10.1038/s41586-018-0217-9
Program Prior Authorization/Medical Necessity- Vijoice® (alpelisib)
Change Control
6/2022 New program.
6/2023 Annual review. Updated references.
6/2024 Annual review. Revised criteria for presumptive PROS if unable to
confirm PIK3CA gene mutation. Updated initial authorization to 12
months. Updated references.
6/2025 Annual review without changes to coverage criteria.
© 2025 UnitedHealthcare Services Inc.
3